Delving into the Latest Updates on 11C-JNJ-63779586 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Alzheimer Disease

Originator Organization

Janssen Research & Development LLC

Active Organization-

Inactive Organization

Janssen Research & Development LLC

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to investigate the total body biodistribution and radiation dosimetry of 11C-JNJ-63779586 by Positron Emission Tomography (PET) in healthy young adult males (Part A); to estimate and compare the uptake, distribution, and clearance of 11C-JNJ-63779586 in the brain by PET between mild Alzheimer Disease (AD) participants (males/females) and age- and gender-matched control participants (Part B), corrected for regional cerebral blood flow differences; and to model the tissue specific kinetics of 11C-JNJ-63779586 in human brain with the appropriate input function (IF) (Part B).

Start Date17 May 2017

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with 11C-JNJ-63779586

Login to view more data

100 Translational Medicine associated with 11C-JNJ-63779586

Login to view more data

100 Patents (Medical) associated with 11C-JNJ-63779586

Login to view more data

100 Deals associated with 11C-JNJ-63779586

Login to view more data